))
Examining Delgocitinib for Chronic Hand Eczema: Results from the DELTA Trials
Manage episode 514930804 series 3397331
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Guest: Robert Bissonnette, MD, FRCPC
The DELTA 1 and DELTA 2 trials examined the efficacy and safety of the topical pan-JAK inhibitor delgocitinib in patients with moderate to severe chronic hand eczema. Based on the findings, no new safety signals were observed, and nearly half of patients achieved a 75 percent improvement in HECSI scores as well as meaningful relief in itch, pain, and quality of life. Here to talk about the trials’ design and findings—as well as his own firsthand experience treating patients who were enrolled in the trials—is board-certified dermatologist Dr. Robert Bissonnette.
…
continue reading
The DELTA 1 and DELTA 2 trials examined the efficacy and safety of the topical pan-JAK inhibitor delgocitinib in patients with moderate to severe chronic hand eczema. Based on the findings, no new safety signals were observed, and nearly half of patients achieved a 75 percent improvement in HECSI scores as well as meaningful relief in itch, pain, and quality of life. Here to talk about the trials’ design and findings—as well as his own firsthand experience treating patients who were enrolled in the trials—is board-certified dermatologist Dr. Robert Bissonnette.
44 episodes
Share
